clobazam has been researched along with Disease Models, Animal in 12 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the molecular effects of the antiepileptic drug clobazam (CLB, 1,5-benzodiazepine), a benzodiazepine effective in the management of epilepsy, we performed a series of experiments using rats with chronic, spontaneous recurrent seizures induced by amygdalar injection of FeCl(3)." | 3.73 | Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. ( Doi, T; Tokumaru, J; Ueda, Y; Willmore, LJ, 2005) |
| "Clobazam (CLB) is a new antiepileptic drug that is the first 1,5-benzodiazepine (BZP) having nitrogen atoms in the 1 and 5 positions of the heterocyclic ring, whose chemical structure was designed to give it a different pharmacological profile from that of 1,4-BZPs." | 2.41 | [A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. ( Nakajima, H, 2001) |
| "Nocturnal frontal lobe epilepsy (NFLE) is an idiopathic partial epilepsy with a family history in about 25% of cases, with autosomal dominant inheritance (autosomal dominant NFLE [ADNFLE])." | 1.46 | Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy. ( Aroni, S; Marrosu, F; Melis, M; Milioli, G; Muntoni, AL; Parrino, L; Pillolla, G; Pistis, M; Puligheddu, M; Sagheddu, C; Terzano, GM, 2017) |
| "The anticonvulsant interaction profile between 1-MeTHIQ and CLB in the mouse MES model was determined using an isobolographic analysis for parallel dose-response relationship curves." | 1.40 | Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model--an isobolographic analysis for parallel dose-response relationship curves. ( Andres-Mach, M; Haratym-Maj, A; Luszczki, JJ; Zagaja, M, 2014) |
| "Clobazam is a 1,5-BZD, which exhibits less cognitive side effects than other benzodiazepines." | 1.39 | Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model in mice: a pharmacokinetic-pharmacodynamic study. ( Besson, M; Daali, Y; Dayer, P; Desmeules, J; Di Lio, A; Zeilhofer, HU, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajak, H | 1 |
| Singh Thakur, B | 1 |
| Singh, A | 1 |
| Raghuvanshi, K | 1 |
| Sah, AK | 1 |
| Veerasamy, R | 1 |
| Sharma, PC | 1 |
| Singh Pawar, R | 1 |
| Kharya, MD | 1 |
| Malik, S | 1 |
| Bahare, RS | 1 |
| Khan, SA | 1 |
| Puligheddu, M | 1 |
| Melis, M | 1 |
| Pillolla, G | 1 |
| Milioli, G | 1 |
| Parrino, L | 1 |
| Terzano, GM | 1 |
| Aroni, S | 1 |
| Sagheddu, C | 1 |
| Marrosu, F | 1 |
| Pistis, M | 1 |
| Muntoni, AL | 1 |
| Luszczki, JJ | 3 |
| Patrzylas, P | 1 |
| Zagaja, M | 3 |
| Andres-Mach, M | 2 |
| Zaluska, K | 1 |
| Kondrat-Wrobel, MW | 1 |
| Szpringer, M | 1 |
| Chmielewski, J | 1 |
| Florek-Luszczki, M | 2 |
| Haratym-Maj, A | 1 |
| Hawkins, NA | 1 |
| Zachwieja, NJ | 1 |
| Miller, AR | 1 |
| Anderson, LL | 1 |
| Kearney, JA | 1 |
| Cao, D | 1 |
| Ohtani, H | 1 |
| Ogiwara, I | 1 |
| Ohtani, S | 1 |
| Takahashi, Y | 1 |
| Yamakawa, K | 1 |
| Inoue, Y | 1 |
| Besson, M | 1 |
| Daali, Y | 1 |
| Di Lio, A | 1 |
| Dayer, P | 1 |
| Zeilhofer, HU | 1 |
| Desmeules, J | 1 |
| Doi, T | 1 |
| Ueda, Y | 1 |
| Tokumaru, J | 1 |
| Willmore, LJ | 1 |
| Fisher, R | 1 |
| Blum, D | 1 |
| Nakajima, H | 1 |
2 reviews available for clobazam and Disease Models, Animal
| Article | Year |
|---|---|
Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamazepine; Cl | 1995 |
[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug].
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clobazam; | 2001 |
10 other studies available for clobazam and Disease Models, Animal
| Article | Year |
|---|---|
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
Topics: Acyclic Monoterpenes; Animals; Anticonvulsants; Binding Sites; Cyclohexenes; Disease Models, Animal; | 2013 |
Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Disease Models, | 2013 |
Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy.
Topics: Adult; Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Disease Models, Animal; D | 2017 |
Effects of arachidonyl-2'-chloroethylamide (ACEA) on the protective action of various antiepileptic drugs in the 6-Hz corneal stimulation model in mice.
Topics: Acetamides; Animals; Anticonvulsants; Arachidonic Acids; Avoidance Learning; Benzodiazepines; Clobaz | 2017 |
Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model--an isobolographic analysis for parallel dose-response relationship curves.
Topics: Animals; Anticonvulsants; Benzodiazepines; Clobazam; Disease Models, Animal; Dose-Response Relations | 2014 |
Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock-induced seizure model and chimney test in mice.
Topics: Acetamides; Animals; Anticonvulsants; Benzodiazepines; Benzoxazines; Clobazam; Disease Models, Anima | 2014 |
Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.
Topics: Animals; Benzodiazepines; Chromosome Mapping; Chromosomes; Clobazam; Disease Models, Animal; Epileps | 2016 |
Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome.
Topics: Age Factors; Animals; Anticonvulsants; Benzodiazepines; Clobazam; Dioxolanes; Disease Models, Animal | 2012 |
Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model in mice: a pharmacokinetic-pharmacodynamic study.
Topics: Animals; Benzodiazepines; Brain; Clobazam; Disease Models, Animal; Dose-Response Relationship, Drug; | 2013 |
Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats.
Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Anticonvulsants; Benzodiazepines; B | 2005 |